Copied
 
 
2022, DKK
04.08.2023
Bruttoresultat

23.003'

Primær drift

239'

Årets resultat

2.735'

Aktiver

77.982'

Kortfristede aktiver

30.311'

Egenkapital

-35.697'

Afkastningsgrad

0 %

Soliditetsgrad

-46 %

Likviditetsgrad

27 %

Resultat
04.08.2023
Årsrapport
2022
04.08.2023
2021
08.08.2022
2020
14.07.2021
2019
21.09.2020
2018
09.07.2019
2017
04.07.2018
2016
07.07.2017
2015
13.06.2016
Nettoomsætning88.097.96794.361.000120.590.00040.638.0006.056.0008.205.0007.832.0006.240.000
Bruttoresultat23.002.82525.983.00058.977.000-22.348.0004.895.0006.825.0005.103.0000
Resultat af primær drift238.697-20.432.00020.929.000-41.660.000-126.0001.700.000478.0000
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter6.269.2996.861.00004.526.000027.567.00033.000961.000
Finansieringsomkostninger-1.051.483-1.397.000-13.108.000-12.877.000-21.497.000-6.097.000-12.787.000-26.210.000
Andre finansielle omkostninger00000000
Resultat før skat2.639.310-17.964.000-2.668.000-47.051.000-8.580.000-80.960.0002.227.000-10.610.000
Resultat2.735.461-23.764.0004.799.000-47.356.000-8.696.000-80.960.000-3.586.000-5.261.000
Forslag til udbytte00000000
Aktiver
04.08.2023
Årsrapport
2022
04.08.2023
2021
08.08.2022
2020
14.07.2021
2019
21.09.2020
2018
09.07.2019
2017
04.07.2018
2016
07.07.2017
2015
13.06.2016
Kortfristede varebeholdninger00000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 16.860.12610.141.00025.727.00045.699.0003.228.0002.694.0007.565.000258.874.000
Likvider13.450.49710.206.00024.259.00010.358.0001.256.0001.193.0003.824.0002.360.000
Kortfristede aktiver30.310.62320.347.00049.986.00056.057.0004.484.0003.887.00011.389.000261.234.000
Immaterielle aktiver og goodwill0012.027.00013.708.0000246.373.000355.469.000341.545.000
Finansielle anlægsaktiver47.671.01954.275.00088.635.00099.751.000261.098.000246.415.000355.511.000341.587.000
Materielle aktiver0694.0001.660.0002.018.00074.000108.000126.00093.000
Langfristede aktiver47.671.01954.969.000102.322.000115.477.000261.172.000246.523.000355.637.000341.680.000
Aktiver77.981.64275.316.000152.308.000171.534.000265.656.000250.410.000367.026.000602.914.000
Aktiver
04.08.2023
Passiver
04.08.2023
Årsrapport
2022
04.08.2023
2021
08.08.2022
2020
14.07.2021
2019
21.09.2020
2018
09.07.2019
2017
04.07.2018
2016
07.07.2017
2015
13.06.2016
Forslag til udbytte00000000
Egenkapital-35.697.311-37.633.000-18.713.000-22.342.00024.769.00031.838.000117.765.000121.929.000
Hensatte forpligtelser00000000
Langfristet gæld til banker00000000
Anden langfristet gæld002.628.0001.296.0000000
Leverandører af varer og tjenesteydelser663.30512.00027.526.00029.900.00026.00069.000240.000277.000
Kortfristede forpligtelser113.678.95386.083.000168.393.000192.580.000240.887.000218.572.000249.261.000480.985.000
Gældsforpligtelser113.678.953112.949.000171.021.000193.876.000240.887.000218.572.000249.261.000480.985.000
Forpligtelser113.678.953112.949.000171.021.000193.876.000240.887.000218.572.000249.261.000480.985.000
Passiver77.981.64275.316.000152.308.000171.534.000265.656.000250.410.000367.026.000602.914.000
Passiver
04.08.2023
Nøgletal
04.08.2023
Årsrapport
2022
04.08.2023
2021
08.08.2022
2020
14.07.2021
2019
21.09.2020
2018
09.07.2019
2017
04.07.2018
2016
07.07.2017
2015
13.06.2016
Afkastningsgrad 0,3 %-27,1 %13,7 %-24,3 %0,0 %0,7 %0,1 %Na.
Dækningsgrad 26,1 %27,5 %48,9 %-55,0 %80,8 %83,2 %65,2 %Na.
Resultatgrad 3,1 %-25,2 %4,0 %-116,5 %-143,6 %-986,7 %-45,8 %-84,3 %
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning -7,7 %63,1 %-25,6 %212,0 %-35,1 %-254,3 %-3,0 %-4,3 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal 22,7 %-1.462,6 %159,7 %-323,5 %-0,6 %27,9 %3,7 %Na.
Soliditestgrad -45,8 %-50,0 %-12,3 %-13,0 %9,3 %12,7 %32,1 %20,2 %
Likviditetsgrad 26,7 %23,6 %29,7 %29,1 %1,9 %1,8 %4,6 %54,3 %
Resultat
04.08.2023
Gæld
04.08.2023
Årsrapport
04.08.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 04.08.2023)
Information om virksomhedens regnskabsklasse:The annual report of Center for Clinical and Basic Research A/S for 2022 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C, as well as provisions applying to reporting class C entities. The annual report for 2022 is presented in DKK
Oplysning om pantsætninger og sikkerhedsstillelser:The Company has not provided any security or other collateral in assets at 31 December 2022.
Beretning
04.08.2023
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual matters As a result of the Management's decision to discontinue the company's activities and dissolve the company, the annual accounts are prepared according to the realization principle (not going concern). Reference is made to the accounting policies for more details.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Board of Directors and executive board have today discussed and approved the annual report of Center for Clinical and Basic Research A/S for the financial year 1 January - 31 December 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business review The Company is dedicated to carrying out clinical research trials on behalf of customers, and is part of the PPD group. PPD is a global contract research organization (CRO), a leading provider of drug development services to the biopharmaceutical industry. Our industry leading, highly experienced investigators focus all their energy on clinical research and helping our customers to deliver life changing therapies to patients. In 2022 the Management decided that the company's activities should be discontinued and the company is expected to be dissolved by voluntary solvent liquidation in 2023 or beginning of 2024. At the time of the preparing of the annual report for 2022, all of the Company's employees have been dismissed, the Company's lease of premises has been terminated and there is no activity.